Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection

Overview

Journal P T

Specialty Pharmacology

Date 2015 Jan 29

PMID 25628507

Citations 22

Authors

William R Truong

Jason J Schafer

William R Short

Affiliations

Soon will be listed here.

Abstract

Once-daily, single-tablet regimens have become integral to the management of human immunodeficiency virus type 1 infection, partly because they may improve adherence due to a lower pill burden. This article reviews the single-tablet options.

Citing Articles

A Model-Based Approach Supporting Abacavir/Dolutegravir/Lamivudine Fixed-Dose Combination Approval in Children Living with HIV-1.

Chandasana H, Buchanan A, McKenna M, Brothers C, Hyatt S, Adkison K J Clin Pharmacol. 2024; .

PMID: 39235061 PMC: 11683174. DOI: 10.1002/jcph.6128.

Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines.

Schwarzmuller M, Lozano C, Schanz M, Abela I, Grosse-Holz S, Epp S Cell Rep Med. 2024; 5(9):101702.

PMID: 39216479 PMC: 11524982. DOI: 10.1016/j.xcrm.2024.101702.

Lower self-reported ART adherence among adolescents in boarding schools compared to day schools.

Wandika B, Nyapara F, Aballa C, Richardson B, Wamalwa D, John-Stewart G J Acquir Immune Defic Syndr. 2024; .

PMID: 38346421 PMC: 11317543. DOI: 10.1097/QAI.0000000000003400.

The changing landscape of HIV-associated kidney disease.

Diana N, Naicker S Nat Rev Nephrol. 2024; 20(5):330-346.

PMID: 38273026 DOI: 10.1038/s41581-023-00801-1.

Identifying the Unmet Medical Needs of HIV-Positive Subjects in Korea: Results of a Nationwide Online Survey.

Lee J, Kim Y, Lee J, Park S, Choi J Infect Chemother. 2023; 55(3):397-402.

PMID: 37794578 PMC: 10551716. DOI: 10.3947/ic.2023.0065.

References

Robertson S, Maldarelli F, Natarajan V, Formentini E, Alfaro R, Penzak S . Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr. 2008; 49(5):513-9. PMC: 9036313. DOI: 10.1097/QAI.0b013e318183a425. View

Zolopa A, Sax P, DeJesus E, Mills A, Cohen C, Wohl D . A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96.... J Acquir Immune Defic Syndr. 2013; 63(1):96-100. DOI: 10.1097/QAI.0b013e318289545c. View

Song I, Mark S, Chen S, Savina P, Wajima T, Peppercorn A . Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects. Drug Alcohol Depend. 2013; 133(2):781-4. DOI: 10.1016/j.drugalcdep.2013.08.009. View

Sax P, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D . Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012; 379(9835):2439-2448. DOI: 10.1016/S0140-6736(12)60917-9. View

Liu P, Foster G, LaBadie R, Gutierrez M, Sharma A . Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol. 2007; 48(1):73-84. DOI: 10.1177/0091270007309703. View

Shah B, Schafer J, DeSimone Jr J . Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. Pharmacotherapy. 2013; 34(5):506-20. DOI: 10.1002/phar.1386. View

Crauwels H, van Heeswijk R, Buelens A, Stevens M, Hoetelmans R . Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers. Int J Clin Pharmacol Ther. 2013; 52(2):118-28. DOI: 10.5414/CP201943. View

Azijn H, Tirry I, Vingerhoets J, de Bethune M, Kraus G, Boven K . TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2009; 54(2):718-27. PMC: 2812151. DOI: 10.1128/AAC.00986-09. View

Damle B, LaBadie R, Crownover P, Glue P . Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol. 2008; 65(4):523-30. PMC: 2291383. DOI: 10.1111/j.1365-2125.2007.03085.x. View

10.

Hodder S, Mounzer K, DeJesus E, Ebrahimi R, Grimm K, Esker S . Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS. 2010; 24(2):87-96. DOI: 10.1089/apc.2009.0259. View

11.

Marinello J, Marchand C, Mott B, Bain A, Thomas C, Pommier Y . Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry. 2008; 47(36):9345-54. PMC: 2660605. DOI: 10.1021/bi800791q. View

12.

DeJesus E, Rockstroh J, Henry K, Molina J, Gathe J, Ramanathan S . Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised,.... Lancet. 2012; 379(9835):2429-2438. DOI: 10.1016/S0140-6736(12)60918-0. View

13.

Lepist E, Zhang X, Hao J, Huang J, Kosaka A, Birkus G . Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int. 2014; 86(2):350-7. PMC: 4120670. DOI: 10.1038/ki.2014.66. View

14.

Crauwels H, van Heeswijk R, Stevens M, Buelens A, Vanveggel S, Boven K . Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013; 15(2):87-101. View

15.

Koteff J, Borland J, Chen S, Song I, Peppercorn A, Koshiba T . A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2012; 75(4):990-6. PMC: 3612717. DOI: 10.1111/j.1365-2125.2012.04440.x. View

16.

Mathias A, Hinkle J, Menning M, Hui J, Kaul S, Kearney B . Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. J Acquir Immune Defic Syndr. 2007; 46(2):167-73. DOI: 10.1097/QAI.0b013e3181427835. View

17.

Gerber J, Rosenkranz S, Fichtenbaum C, Vega J, Yang A, Alston B . Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr. 2005; 39(3):307-12. DOI: 10.1097/01.qai.0000167156.44980.33. View

18.

Zhu M, Kaul S, Nandy P, Grasela D, Pfister M . Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob Agents Chemother. 2009; 53(6):2346-53. PMC: 2687212. DOI: 10.1128/AAC.01120-08. View

19.

Nachega J, Parienti J, Uthman O, Gross R, Dowdy D, Sax P . Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis. 2014; 58(9):1297-307. PMC: 3982838. DOI: 10.1093/cid/ciu046. View

20.

Cohen C, Andrade-Villanueva J, Clotet B, Fourie J, Johnson M, Ruxrungtham K . Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011; 378(9787):229-37. DOI: 10.1016/S0140-6736(11)60983-5. View